Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Colorectal Connection Management (CCM) was a medical technology company and a subsidiary of Live Tissue Connect, which operated under the parent organization CSMG Technologies. Founded to commercialize the 'Live Tissue Connect' (LTC) platform, the company focused on applying high-frequency radiofrequency (RF) tissue welding technology to colorectal surgical procedures. This innovative approach was designed to fuse soft biological tissues, such as the intestines, as an alternative to traditional mechanical closure methods like sutures and staples. The technology originated from the E.O. Paton Electric Welding Institute in Ukraine and received CE Mark approval for its VAD.400 generator system. Despite performing thousands of successful surgeries in Eastern Europe and establishing a licensing agreement with ConMed Corporation, the company failed to achieve sustainable commercial operations in the United States. Colorectal Connection Management became inactive following the SEC's revocation of its parent company's securities registration in 2012.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Colorectal Connection Management.